Experimental IDH drug trial halted early – what we know
NCT ID NCT04764474
First seen Feb 02, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-stage study tested an experimental drug called HMPL-306 in 46 adults with advanced blood cancers that have a specific genetic change (IDH mutation). The main goals were to find a safe dose and check for side effects. The study was stopped early, so results are limited, but it aimed to help people who had run out of standard treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISOCITRATE DEHYDROGENASE GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Froedtert-Medical College of WI
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Fe
Valencia, Valencia, 46026, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario de Salamanca
Salamanca, 58-182, Spain
-
Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Massachusetts Medical School
Worcester, Massachusetts, 01655, United States
-
Winship Cancer Institute - Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.